Moreover, further research will evaluate whether the BPTF-specific PROTAC degrader could enhance NK cell-mediated antitumor efficacy against other malignancies with significant BPTF overexpression, such as lung cancer and breast cancer. This evidence concerns the gene BPTF and lung carcinoma.